Nupathe Inc.

Zynerba Pharmaceuticals, Inc.

Teva Pharmaceuticals International Gmbh

Harmony Biosciences Management, Inc.

University of Pennsylvania

Terri Sebree

Donna Gutterman

Marcel Bonn-Miller

John Messenheimer

Mark Pierce

Nancy Tich

Carol O'neill

Carter R Anderson

Russell L Morris

Steven Siegel

Michael Horstmann

Mohammad Sameti

Robert P Stathopulos

Mihai A Vinatoru

Carol O'Neill

The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.

Treatment of behavioral impairment in developmental and epileptic encephalopathy

The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.

Treatment of fragile X syndrome with cannabidiol

The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.

Treatment of autism with cannabidiol

The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q 11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q 11.2 deletion syndrome are treated in the subject.

Treatment of 22Q11.2 deletion syndrome with cannabidiol

Treatment of Fragile X Syndrome with cannabidiol

The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.2 deletion syndrome are treated in the subject.

Treatment of fragile x syndrome with cannabidiol

Biodegradable implants comprising dopamine modulating compounds are described.

Implants for the treatment of dopamine associated states

Methods for treating nausea and migraine by iontophoretically administering triptan compounds are provided.

Methods for iontophoretically treating nausea and migraine

Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.

Growing community of inventors

Gladwyne, PA, United States of America

Terri Sebree